- Home
- NTHI vs TNXP Comparison
NTHI vs TNXP Comparison
Compare NTHI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- TNXP
- Stock Information
- Founded
- NTHI 2008
- TNXP 2007
- Country
- NTHI United States
- TNXP United States
- Employees
- NTHI N/A
- TNXP N/A
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- NTHI Health Care
- TNXP Health Care
- Exchange
- NTHI Nasdaq
- TNXP Nasdaq
- Market Cap
- NTHI 211.9M
- TNXP 173.9M
- IPO Year
- NTHI N/A
- TNXP N/A
- Fundamental
- Price
- NTHI $10.10
- TNXP $18.49
- Analyst Decision
- NTHI
- TNXP Buy
- Analyst Count
- NTHI 0
- TNXP 1
- Target Price
- NTHI N/A
- TNXP $70.00
- AVG Volume (30 Days)
- NTHI 42.8K
- TNXP 851.8K
- Earning Date
- NTHI 11-19-2025
- TNXP 11-07-2025
- Dividend Yield
- NTHI N/A
- TNXP N/A
- EPS Growth
- NTHI N/A
- TNXP N/A
- EPS
- NTHI N/A
- TNXP N/A
- Revenue
- NTHI $59,990.00
- TNXP $9,831,000.00
- Revenue This Year
- NTHI N/A
- TNXP $14.79
- Revenue Next Year
- NTHI N/A
- TNXP $933.49
- P/E Ratio
- NTHI N/A
- TNXP N/A
- Revenue Growth
- NTHI N/A
- TNXP N/A
- 52 Week Low
- NTHI $3.20
- TNXP $6.76
- 52 Week High
- NTHI $25.00
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- NTHI N/A
- TNXP 31.62
- Support Level
- NTHI N/A
- TNXP $18.53
- Resistance Level
- NTHI N/A
- TNXP $20.58
- Average True Range (ATR)
- NTHI 0.00
- TNXP 1.09
- MACD
- NTHI 0.00
- TNXP 0.41
- Stochastic Oscillator
- NTHI 0.00
- TNXP 7.04
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.